Cibus's Entire Licensing Pipeline Hinges on Gene-Editing Claims That Lack Commercial-Scale Proof
Cibus, Inc. markets its RTDS and Trait Machine platforms as breakthrough gene-editing technologies, but those claims remain opinion-classified with no commercial-scale validation. If field trials underperform or licensed traits disappoint seed company partners, the company's licensing revenue pipeline faces collapse. The risk is rated catastrophic in severity, making it a critical watch item for investors in agricultural biotech.
Salvado•